Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on adaptogen supplements. It is informational only and is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before starting any new supplement, especially if you take medications or have a medical condition.

TL;DR

• Ashwagandha (specifically the KSM-66 and Sensoril extracts) has substantially more human RCT data than reishi or shiitake extract — particularly in the stress, cortisol, and sleep domains.
• Reishi has biological plausibility for immune marker modulation and some trial support, but most published data comes from clinical populations (cancer patients) rather than healthy adults.
• Shiitake extract has the thinnest supplement-trial base of the three; the published food-consumption studies do not translate directly to concentrated extract products.
• Side effect profiles are acceptable at standard doses in studied timeframes for both categories, but both ashwagandha and reishi have case reports of hepatotoxicity at higher doses.
• Neither category substitutes for addressing sleep, exercise, diet, and stress management with established behavioral approaches.

The decision most buyers are actually facing

Ashwagandha is on the shelf at every supplement retailer and gets mentioned on virtually every stress-management or wellness podcast. Reishi mushroom and shiitake extract occupy a parallel section often labeled “Japanese adaptogens” or “medicinal mushrooms,” with labels that lead with thousands of years of traditional use.

The question most buyers are quietly asking is: are the Japanese options actually well-studied, or is ashwagandha just better-marketed? Or the reverse — is the traditional-use framing covering for gaps in the RCT base?

The comparison is not close on trial quantity in 2026. Ashwagandha has considerably more human RCT data. Whether that matters for your specific goals depends on what you are trying to address.

What “adaptogen” actually means pharmacologically

“Adaptogen” is a marketing category more than a pharmacological one. Soviet pharmacologist Nikolai Lazarev coined the term in 1947 to describe plants that nonspecifically increase resistance to stress. The criteria remain loose: reduce stress-response markers, minimal toxicity, normalizing effect across conditions.

Ashwagandha, reishi, shiitake, maitake, rhodiola, and a dozen other plants and fungi all carry the label. The grouping implies mechanistic similarity that does not exist — the active compounds, trial evidence, and plausible mechanisms differ substantially across all of them. “Adaptogen” is useful for finding products on a shelf; it is not useful for comparing evidence.

Ashwagandha: the larger RCT pool

Ashwagandha (Withania somnifera) is an Ayurvedic root extract. Two standardized extracts — KSM-66 (from the root) and Sensoril (from root and leaf) — account for the large majority of published human trials. A product that does not identify its extract type on the label is not using the same inputs the research studied.

Stress and cortisol

The most replicated effect across ashwagandha trials is reduced perceived stress and lower serum cortisol.

Chandrasekhar et al. 2012 (Journal of the Indian System of Medicine) tested KSM-66 at 300 mg twice daily in 64 adults with chronic stress over 60 days. Perceived Stress Scale scores and morning serum cortisol both fell significantly in the ashwagandha group relative to placebo — cortisol by approximately 28%. The trial is small and uses a surrogate endpoint, but the cortisol signal has appeared consistently in independent replications using both KSM-66 and Sensoril at doses of 240–600 mg/day over 8–12 weeks.

The effect size is moderate. It is not the effect magnitude of a pharmaceutical anxiolytic. It is consistent enough across independent groups to be taken seriously by a skeptical reader.

Sleep quality

Langade et al. 2019 (PLOS ONE) tested 300 mg KSM-66 twice daily in 60 adults over 10 weeks and found significantly improved Pittsburgh Sleep Quality Index (PSQI) scores, reduced sleep onset latency, and higher sleep efficiency on actigraphy relative to placebo. A 2021 follow-up by the same group in healthy adults without diagnosed insomnia found similar improvements in total sleep time and efficiency. The effect size is clinically meaningful — not a pharmaceutical, but comparable to what behavioral sleep-hygiene interventions produce in RCTs.

The proposed mechanism involves withanolide-mediated modulation of GABA receptors and downstream cortisol reduction; neither is fully characterized in humans.

Physical performance

A smaller body of trials in trained adults suggests modest improvements in 1-repetition maximum, muscle recovery time, and VO2 max. Effect sizes are consistent but small, and studied populations skew toward young adult males, limiting how far the findings generalize. These are the least robust findings in the ashwagandha literature.

What the trial evidence does not support

• Prevention or treatment of any specific disease
• Immune function changes in healthy adults (this is largely absent from the ashwagandha RCT literature; most immunological claims trace to Ayurvedic tradition rather than controlled trials)
• Long-term health outcomes beyond the timeframes studied (12–24 weeks in most trials)

Reishi and shiitake extract: where the evidence stands

Reishi (Ganoderma lucidum / 霊芝)

Reishi is the Japanese and Chinese medicinal mushroom most commonly marketed for immune support and fatigue reduction. Active compounds include beta-glucans (polysaccharides) and triterpenes (ganoderic acids). Hot-water extraction yields polysaccharides; dual extraction (water and alcohol) adds triterpenes.

The human trial evidence for reishi is substantially smaller than for ashwagandha, and a significant portion comes from clinical rather than healthy-adult populations.

• Gao et al. 2003 and 2004 conducted placebo-controlled trials of reishi polysaccharide extract in cancer patients receiving chemotherapy, finding improvements in self-reported quality of life and some immune marker changes. These findings apply to a specific clinical population and do not translate directly to healthy-adult supplementation.
• A 2012 randomized, placebo-controlled trial in Taiwan (n=132) tested reishi extract in non-clinical subjects with fatigue and found improvements in fatigue scores over 8 weeks. This is a larger sample than most reishi trials and represents more directly relevant evidence for general consumers, though the design has limitations in blinding and outcome selection.
• Immune marker changes — NK cell activity, certain cytokine profiles — appear in multiple small trials. Whether these biomarker shifts produce meaningful health differences for healthy adults is not established in adequately powered outcome trials.

The supplements.json master data for this site categorizes Japanese medicinal mushroom extracts as “preliminary across most claims,” which accurately reflects the published literature as of 2026.

Shiitake extract (Lentinus edodes / 椎茸エキス)

Shiitake is more familiar as a food than as a supplement in the West. The compounds studied in shiitake extract include lentinan (a beta-glucan) and eritadenine.

• A small Japanese trial published in 2013 examined shiitake extract supplementation over 8 weeks and found modest improvements in lipid markers (LDL-C) relative to control. Sample sizes were small and the findings have not been replicated in independent larger trials.
• A 2015 randomized trial (Journal of the American College of Nutrition, n=52) found that consuming shiitake mushrooms (whole dried, not extract) daily for 4 weeks was associated with improved gut immunity markers (secretory IgA) and reduced C-reactive protein relative to baseline. Notably, this was a food consumption study — not a concentrated extract trial — which limits direct application to supplement products.

The evidence base for shiitake supplement extract is thinner than for reishi, and substantially thinner than for ashwagandha in the domains most people are shopping for.

Maitake

Maitake (Grifola frondosa) is often grouped with the Japanese adaptogen category. The D-fraction extract has been studied for blood glucose markers and immune function in small trials. Evidence remains preliminary and mid-sized RCTs in healthy adults are largely absent as of 2026.

Side-by-side evidence snapshot

Domain	Ashwagandha (KSM-66/Sensoril)	Reishi	Shiitake extract
Perceived stress	Multiple RCTs; moderate effect, replicated	No direct RCT data	No data
Sleep quality	Multiple RCTs; replicated	No RCT data in healthy adults	No data
Cortisol reduction	Replicated in stressed adults	No replicated data	No data
Fatigue	Mixed; more signal in stressed populations	Small trials; clearer in cancer-related fatigue	Limited
Immune markers	Not a primary studied domain	Small trials, largely clinical populations	One food trial; no extract RCTs
Cholesterol / lipid markers	Not a primary domain	Limited	Small extraction trials

Side effects and interactions

Both categories have acceptable tolerability profiles at studied doses over 8–24 week durations. Neither is without cautions.

Ashwagandha

Common adverse events in trials: mild digestive upset, drowsiness, occasional headache. A small but consistent number of case reports in the peer-reviewed literature describe hepatotoxicity (liver enzyme elevation) associated with ashwagandha use, often at higher-than-studied doses or with extended use beyond trial durations. The signal is not large enough to be a contraindication for healthy adults at standard doses, but warrants caution for anyone with existing liver concerns.

Drug interactions to be aware of:

• Thyroid hormones: some trials show ashwagandha is associated with increased TSH, T3, and T4. Anyone taking thyroid medication should discuss this before starting.
• Additive sedative effects with benzodiazepines, sleep medications, and other CNS depressants.
• Not studied in pregnancy or lactation; avoid in those populations.

Reishi

Generally well-tolerated in trials. Reported adverse events include digestive upset and, rarely, skin reactions. Case reports of hepatotoxicity exist in the literature at higher doses, similar to ashwagandha.

Drug interactions to be aware of:

• Anticoagulant effects: reishi has shown mild anticoagulant properties in some studies. Anyone on warfarin, aspirin in anticoagulant doses, or newer anticoagulants (apixaban, rivaroxaban) should be aware.
• Immune modulation: this cuts in both directions. Anyone with an autoimmune condition or taking immunosuppressant medication should not take reishi without first discussing it with a physician.
• Not studied in pregnancy; avoid in those populations.

How to buy

Ashwagandha

Look for KSM-66 or Sensoril on the label. These are the standardized extracts used in the published trials; a product without a specified extract type is not using the same ingredients the research studied.

Typical studied dose is 300–600 mg/day of standardized extract, often split into two 300 mg doses. Doses at the higher end of the range have not shown proportionally greater effects in the available comparative data.

iHerb carries KSM-66 products from multiple brands including Jarrow Formulas, NOW Foods, and NaturesPlus at mid-range pricing. Amazon carries the same brands with subscription-pricing options. Ask for the current certificate of analysis before committing to a new brand.

Reishi

The extraction method matters more than the brand name. Look for:

• Hot-water extraction for polysaccharides and beta-glucans (the immune marker-associated fraction in most trials).
• Dual extraction (water and alcohol) if you want both polysaccharides and triterpenes.
• Fruiting body rather than mycelium-on-grain substrate. Mycelium-on-grain products are cheaper but contain substantial starch from the grain medium rather than mushroom-specific compounds.

Real Mushrooms and Host Defense are among the more transparently documented brands for sourcing and extraction method. Both are available on iHerb and Amazon.

Dosing: most trials used polysaccharide-equivalent amounts, not standardized whole-extract weights, so dose guidance is less precise than for ashwagandha. A common consumer approach is 1–2 g of fruiting-body powder or 300–600 mg of concentrated extract daily.

Shiitake extract

The supplement market for isolated shiitake extract is smaller and less quality-filtered than for reishi or ashwagandha. The published evidence is largely from whole-food consumption rather than concentrated extracts, so adding dried shiitake mushrooms to the diet is closer to what the relevant human studies actually examined than buying an extract capsule.

Who should talk to a doctor before starting

• Anyone taking thyroid medication (ashwagandha interaction with hormone levels)
• Anyone on anticoagulants or blood thinners (reishi interaction)
• Anyone with an autoimmune condition (immune modulation from both categories)
• Anyone with liver disease or elevated liver enzymes (case reports of hepatotoxicity with both)
• Pregnant or breastfeeding individuals
• Anyone taking immunosuppressant medication

This is not exhaustive. The relevant question for anyone with a chronic condition or prescription medications is not “is this supplement safe for healthy adults” but “is it safe given my specific situation” — which is a conversation for a clinician with your full chart.

Where the evidence sits in 2026

Ashwagandha, specifically KSM-66 and Sensoril extracts, has a more developed human trial base than reishi or shiitake extract for the outcomes most people are looking for when they buy adaptogens: stress reduction, sleep quality, and general fatigue. Effect sizes are moderate, the safety profile at standard doses is acceptable, and the replicated cortisol and sleep findings make it the better-evidenced option for those specific goals.

Reishi has a real — if preliminary — human trial base, clearer evidence in specific clinical populations (cancer-related fatigue, immune markers), and a biological rationale for immune modulation. Whether that translates to meaningful benefit for healthy adults in standard supplement form remains an open question pending better-powered trials.

Shiitake extract, as a concentrated supplement, is running ahead of its evidence. The food-consumption data is more interesting than the supplement-specific data.

For someone deciding between them: if stress and sleep quality are the primary goals, the evidence currently favors ashwagandha. If Japanese sourcing and tradition matter independently, reishi is a legitimate option with a genuine (if preliminary) trial base. There is no human evidence for stacking both rather than choosing one.

Neither replaces sleep hygiene, regular exercise, diet quality, or stress-management practices that have stronger and more consistent evidence behind them than any supplement in this category.

---

See also: NMN vs NR: what human trials actually compare on dose, cost, and safety, Japanese longevity habits backed by research.